Genesis Biomed Expects to Increase Revenues by 28% in 2022 to €1.6 Million

Genesis Biomed is optimistic about the end of the year. The Spanish consulting firm specializing in the biomedical sector expects to end 2022 with a turnover of €1.6 million, representing a 28% rise compared to 2021, Genesis Biomed explains in a statement.

Founded in May 2017 by Josep Lluís Falcó and Natalia de la Figuera, Genesis Biomed offers advisory services for entrepreneurs in the field of biomedicine and healthcare, both in the development of their business plan and in the process of fundraising and negotiation with family offices, business angels and other venture capital agents.

So far this year, the consulting firm has helped to close the financing round led by Mowoot (one million euros), a company that has developed and is already marketing a patented medical device for the treatment of chronic constipation.

Genesis Biomed has also helped Thytech, a spin-off of the Instituto de Investigación Sanitaria Gregorio Marañón (Iisgm), which has created an allogeneic therapy of Treg cells from thymic tissue for application in autoimmune diseases, such as acute respiratory distress syndrome and organ transplantation, to close a round of €650,000.

Read more about Genesis Biomed with our companion app, Born2Invest, available for free. Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

Genesis Biomed has helped its clients close a total of 19 rounds of financing since its incorporation

With these last two operations, Genesis Biomed has helped its clients close a total of 19 rounds of financing since its incorporation, participating in the launch of twelve start-ups and spin-offs. The company is currently in two fundraising processes for amounts of five million euros and one million euros.

In parallel, Genesis Biomed also invests in projects in very early stages with the aim of valuing them and reaching key milestones that bring innovation closer to the market and, at the same time, generate exit scenarios that allow an attractive return on investment.

In this sense, and with the idea of giving continuity to the Genesis Ventures fund, currently in the disinvestment phase, the company has set up its second vehicle, Genesis Tech Transfer Boost initially endowed with one million euros and aimed at early-stage projects in the field of healthcare research. Headquartered at the Barcelona Science Park and with offices in Madrid, Genesis Biomed has a team of fifteen professionals. Since its incorporation, the consultancy firm has worked on 253 innovation projects.

__

(Featured image by martaposemuckel via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.